Company Profile

Reported as having ceased operations in December 2018, BioSense Technologies had been a biomedical company developing technology used rapidly to diagnose infectious diseases. The company is working on platform technologies for testing clinical specimens that are able to identify antibiotic resistance and determine the most suitable treatment. Bacterial infection is a constant threat to the health of all people as antibiotic resistance, the ability of bacteria to defeat once powerful drugs, significantly challenges the ability to cure diseases and is an emerging crisis. The firm is developing Z-Sense technology, a new approach for treating infectious disease that is able to determine the susceptibility of bacteria to therapeutic agents in 30 minutes or less, significantly faster than currently used testing methods. The company is developing a proprietary new rapid platform technology to determine the chemosensitivity of difficult to culture cancer cells and antibiotic resistant infectious disease specimens. The technology is also being used to detect contaminant bacteria in complex samples and many other clinical applications.